With the demand for cell and gene therapies mounting, CDMO Cognate BioServices is looking to swiftly expand its U.S. headquarters with two new facilities—and it's not stopping there. Its dedicated ...
Cognate BioServices has acquired UK and Sweden-based Cobra Biologics, an advanced therapy CDMO that specializes in providing manufacturing services for the plasmid DNA and viral vector. No financial ...
EW Healthcare Partners has invested in Cognate BioServices. Financial terms weren’t announced. Cognate BioServices is a contract development and manufacturing organization. BALTIMORE and MEMPHIS, Tenn ...
Cobra Biologics, the gene therapy division of the Cognate BioServices’ group, began a multi-phase augmentation of its plasmid DNA services as a continuation of its gene therapy services’ expansion ...
BETHESDA, Md., May 28, 2019 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today ...
(RTTNews) - Charles River Laboratories International, Inc. (CRL) reported fourth-quarter earnings per share on a non-GAAP basis of $2.39, an increase of 18.9% from last year. On average, 16 analysts ...
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has signed a definitive agreement to acquire Cognate BioServices, Inc., a premier ...
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of Cognate BioServices, Inc.
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Cognate’s revenue for 2021 is projected at $140 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results